CCL20 and melanoma: Previous preclinical studies have demonstrated that DNA vaccines comprising melanoma antigen(s) fused to MIP3α delayed tumor growth, prolonged survival, and enhanced T-cell immunity in the B16F10 melanoma model[2–4].